Levi & Korsinsky, LLP announces that an ITRM class action lawsuit has been filed on behalf of investors who purchased Iterum Therapeutics Plc (ITRM) securities between November 30, 2020, and July 23, 2021 For more on the ITRM Lawsuit please contact us today.

According to the Iterum Therapeutics lawsuit, throughout the Class Period defendants made false and/or misleading statements and/or failed to disclose that: (i) the sulopenem New Drug Application (“NDA”) lacked sufficient data to support approval for the treatment of adult women with UTIs caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.

TO LEARN MORE ABOUT THE ITRM CLASS ACTION LAWSUIT, CLICK HERE

If you suffered a loss in Iterum Therapeutics you have until October 4, 2021, to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.

CONTACT:

Levi & Korsinsky, LLP

Joseph E. Levi, Esq.

55 Broadway, 10th Floor

New York, NY 10006

jlevi@levikorsinsky.com

Tel: (212) 363-7500

Fax: (212) 363-7171

www.zlk.com